ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
Dow Jones
38.675,68
1,18%
Euro vs US Dollar
1,07725
-0,01%
Bitcoin
63.624,80
1,17%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NYSE
  6. Zymeworks Inc (ZYME)

  7. Zymeworks Inc (ZYME) News

ZYME

Zymeworks (ZYME)

Zymeworks Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NYSE:ZYME
DatumZeitQuelleÜberschriftSymbolFirma
29/06/202322h12Edgar (US Regulatory)Current Report Filing (8-k)NYSE:ZYMEZymeworks Inc
21/06/202322h05Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ZYMEZymeworks Inc
12/06/202322h26Edgar (US Regulatory)Amended Securities Registration (section 12(b)) (8-a12b/a)NYSE:ZYMEZymeworks Inc
12/06/202322h07Edgar (US Regulatory)Current Report Filing (8-k)NYSE:ZYMEZymeworks Inc
05/06/202312h03Edgar (US Regulatory)Current Report Filing (8-k)NYSE:ZYMEZymeworks Inc
03/06/202301h23PR Newswire (US)Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract CancersNYSE:ZYMEZymeworks Inc
18/05/202314h41Edgar (US Regulatory)Current Report Filing (8-k)NYSE:ZYMEZymeworks Inc
16/05/202314h31Edgar (US Regulatory)Current Report Filing (8-k)NYSE:ZYMEZymeworks Inc
08/05/202323h20Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NYSE:ZYMEZymeworks Inc
08/05/202322h14Edgar (US Regulatory)Current Report Filing (8-k)NYSE:ZYMEZymeworks Inc
28/04/202322h18Edgar (US Regulatory)Amended Annual Report (10-k/a)NYSE:ZYMEZymeworks Inc
26/04/202314h31Edgar (US Regulatory)Current Report Filing (8-k)NYSE:ZYMEZymeworks Inc
10/04/202322h46Edgar (US Regulatory)Current Report Filing (8-k)NYSE:ZYMEZymeworks Inc
15/03/202321h17Edgar (US Regulatory)Current Report Filing (8-k)NYSE:ZYMEZymeworks Inc
14/03/202322h01Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ZYMEZymeworks Inc
07/03/202323h25Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NYSE:ZYMEZymeworks Inc
07/03/202322h09Edgar (US Regulatory)Current Report Filing (8-k)NYSE:ZYMEZymeworks Inc
14/02/202322h47Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NYSE:ZYMEZymeworks Inc
14/02/202322h02Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NYSE:ZYMEZymeworks Inc
14/02/202320h38Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NYSE:ZYMEZymeworks Inc
10/02/202323h29Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NYSE:ZYMEZymeworks Inc
25/01/202314h30Business WireZymeworks Announces Participation in Upcoming Investor ConferencesNYSE:ZYMEZymeworks Inc
24/01/202300h01Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ZYMEZymeworks Inc
19/01/202314h11Edgar (US Regulatory)Current Report Filing (8-k)NYSE:ZYMEZymeworks Inc
19/01/202313h45PR Newswire (US)Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal AdenocarcinomaNYSE:ZYMEZymeworks Inc
19/01/202313h45PR Newswire (US)Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal AdenocarcinomaNYSE:ZYMEZymeworks Inc
12/01/202322h48Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ZYMEZymeworks Inc
04/01/202322h22Edgar (US Regulatory)Current Report Filing (8-k)NYSE:ZYMEZymeworks Inc
04/01/202322h15Business WireZymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023NYSE:ZYMEZymeworks Inc
03/01/202323h02Edgar (US Regulatory)Statement of Ownership (sc 13g)NYSE:ZYMEZymeworks Inc
 Showing the most relevant articles for your search:NYSE:ZYME

Kürzlich von Ihnen besucht

USOTC
BNPQY
BNP Paribas (QX)
CCOM
US500
US 500
USOTC
DTEGY
Deutsche Telekom (QX)
CCOM
US30
US 30
NYSE
NKE
Nike
COIN
BTCUSD
Bitcoin
AMEX
XLV
Health Care Select Sector
NYSE
KO
Coca Cola
TG
NOV
Novo Nordisk
NASDAQ
TSLA
Tesla
NYSE
DIS
Walt Disney
USOTC
RHHBY
Roche (QX)
NYSE
MRK
Merck
DBI
TDXP
Tec DAX
NYSE
MCD
McDonalds
TG
D7G
Nel ASA
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten